Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification

Table 1

Diagnosis of FNH and HCA performed in different academic centers.

	HCA		FNH		No final diagnosis
	Surgery	Biopsy	Surgery	Biopsy	Surgery	Biopsy
French (from 2008 to 2011)
(1) Besançon	4 (4♀)	10	13	3	0	0
(2) Bordeaux	49 (44♀)	16	27	29	0	2
(3) Caen	22 (20♀)	6	19	6	0	0
(4) Créteil	14 (13♀); 2 with HCC	19; 3 with HCC	19	13	0	0
(5) Grenoble	19 (18♀)	18	3	12	0	1
(6) Lille	31 (26♀); 1 with HCC	30	25	39	2	6
(7) Lyon (1)	49 (41♀); 4 with HCC	13	17	16	4	7; (1 with HCC)
(8) Lyon (2)	16 (13♀); 1 with HCC	25	14	22	0	4
(9) Montpellier	32 (31♀); 1 with HCC	28	15	25	3	1
(10) Nice	32 (31♀); 1 with HCC	28	3	25	3	1
(11) Paris (St. Antoine)	11 (9♀); 1 with HCC	13	20	14	0	2; (1 with HCC)
(12) Villejuif (Gustave Roussy)	1 (1♀)	3	5 (4♀)	6	0	4
International
(1) Baltimore (from 1984 to 2012)	63 (61♀); 7 with HCC	6	79	54	4	8
(2) Brussels; (Cliniques universitaires; Saint-Luc-UCL); (1992–2012)*	37 (33♀): 21 IHCA, 10 H-HCA, 1 with IHCA + H-HCA, 3  β-HCA (2 with HCC), 2 UHCA	14	22	14
(3) Heidelberg (2007–2011)	11 (11♀): 9 IHCA, 1 H-HCA, 1 with IHCA + H-HCA		34
(4) London Kings (1998–2011)	35 (30♀): 18 IHCA, 7 H-HCA, 1  β-HCA, 9 UHCA
(5) NY (Mt Sinai) (2007–2011)*	27: 9 H-HCA, 11 I-HCA, 7 UHCA		15
(6) San Francisco; (selected cases)	12 (10♀): 2 IHCA, 3 H-HCA (1 with HCC, 1 borderline), 3  β-HCA (2 with HCC, 1 borderline), 4 UHCA (1 with HCC)
(7) Seattle (2008–2011)	9 (7♀): 3 IHCA, 3 H-HCA, 1  β-HCA, 2 UHCA		1		1
(8) Seoul (2008–2011)	2 (1♀): 1  β-IHCA, 1  β-HCA (1 with HCC)		4 (3♀)
(9) Singapore (selected cases)	2 (2♀): 1  β-IHCA (with HCC), 1 H-HCA
(10) Taiwan	12 (5♀): 3 IHCA, 2  β-HCA, 1 H-HCA, 6 UHCA

∗See papers in this issue for additional information.